|
[1]
|
Real-world Biomarker Testing Patterns in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-based Oncology Practice Setting
Clinical Lung Cancer,
2023
DOI:10.1016/j.cllc.2023.03.002
|
|
|
|
|
[2]
|
Real-world ALK Testing Trends in Patients With Advanced Non–Small-Cell Lung Cancer in the United States
Clinical Lung Cancer,
2023
DOI:10.1016/j.cllc.2022.09.010
|
|
|
|
|
[3]
|
Diversity and Disparities in Lung Cancer Outcomes Among Minorities
The Cancer Journal,
2023
DOI:10.1097/PPO.0000000000000689
|
|
|
|
|
[4]
|
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
Lung Cancer,
2022
DOI:10.1016/j.lungcan.2022.03.004
|
|
|
|
|
[5]
|
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
Journal of Clinical Medicine,
2022
DOI:10.3390/jcm11226738
|
|
|
|
|
[6]
|
European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review
Drugs - Real World Outcomes,
2021
DOI:10.1007/s40801-021-00261-8
|
|
|
|
|
[7]
|
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists
Clinical Lung Cancer,
2021
DOI:10.1016/j.cllc.2021.05.006
|
|
|
|
|
[8]
|
Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
Targeted Oncology,
2020
DOI:10.1007/s11523-020-00718-w
|
|
|
|
|
[9]
|
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
Journal of Clinical Medicine,
2020
DOI:10.3390/jcm9061870
|
|
|
|